Apolipoprotein C2 DeficiencySymptoms, Doctors, Treatments, Advances & More
Apolipoprotein C2 Deficiency Overview
Learn About Apolipoprotein C2 Deficiency
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Office
Joseph Witztum is an Endocrinologist practicing medicine in La Jolla, California. Dr. Witztum is rated as an Elite provider by MediFind in the treatment of Apolipoprotein C2 Deficiency. He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Apolipoprotein C2 Deficiency, Familial Lipoprotein Lipase Deficiency, Familial Hypertriglyceridemia, and Antigen-Peptide-Transporter 2 Deficiency.
Office
Sotirios Tsimikas is a Cardiologist practicing medicine in La Jolla,, California. Dr. Tsimikas is rated as an Elite provider by MediFind in the treatment of Apolipoprotein C2 Deficiency. He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses High Cholesterol, Apolipoprotein C2 Deficiency, Familial Lipoprotein Lipase Deficiency, Percutaneous Coronary Intervention (PCI), and Stent Placement.
Baylor Medicine Atherosclerosis
Christie Ballantyne is a Cardiologist practicing medicine in Houston, Texas. He has been practicing medicine for over 44 years. Dr. Ballantyne is rated as an Elite provider by MediFind in the treatment of Apolipoprotein C2 Deficiency. He is also highly rated in 24 other conditions, according to our data. His clinical expertise encompasses Familial Hypertriglyceridemia, High Cholesterol, Atherosclerosis, Coronary Artery Bypass Graft (CABG), and Heart Bypass Surgery.
Summary: Type I hyperlipoproteinemia (T1HLP, also known as familial chylomicronemia syndrome or FCS) is a rare diseasewhere the blood triglycerides (fats) are very high. It is caused by lack of certain enzymes and proteins in the bodythat are important in disposing circulating fats from blood. Treatment of T1HLP patients who have very high levels of blood fats (≥ 1,000 mg/dL) is challenging as conventional...
Summary: This is an open-label, single-arm, dose-escalation Phase I clinical trial to evaluate the safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) of CS-121, an in vivo base editing therapy delivered by lipid nanoparticles targeting APOC3, in adult participants (18-55 years) with familial chylomicronemia syndrome (FCS).